PDF file: EURASNET Annual Report 2008

224 Schümperli's group willfurther exploit the mouseSMA model mentioned aboveto: (i) determine the timepoint when SMN productionis critical and requirestherapeutic boosting; (ii)study the ability of mutantSMN to counteract the SMAphenotype; (iii) study the roleof SMN in motoneurons; (iv)develop ways to deliver thetherapeutic U7 transgene tomotoneurons. Additionallythey will further improvetheir U7-based exon skippingstrategy.Concerning the analysis ofthe role of PTB inpseudoexon splicing, thegroup has just started a studyto look at whether PTB-nPTBor other neuron-specificsplicing regulators affect thesplicing of agrin, a proteinimportant for synapseestablishment and/ormaintenance. (month 42)225 Eperon's group willinvestigate the possibility ofusing TOES to stimulatesplicing of exons damaged bymutation in cystic fibrosis(collaboration with Barallelab) and of undamagedskipped exons in genes withroles in the development ofleukaemia. (month 42)229 Feasibility study to use massspectrometrey based analysisfor "Spatial Proteomics"where quantification of therelative distribution ofcellular proteins betweendifferent cellularcompartments will beanalyzed in parallel (month42)230 Identification and/or analysisof alternative splicing byhigh-throughput sequencing(month 42)231 Feasibility study to determinewhether analyticalultracentrifugations can beused to determine theassembly of RNA bindingproteins on model RNAs(month 42)232 Experimental setup toelucidate the “code” of RNAinteraction as mediated byRRM domains (month 42)14 Tazi O CO 4214 Tazi O CO 4215 Séraphin O CO 4215 Séraphin O CO 4215 Séraphin O CO 4215 Séraphin O CO 42236